Longevity, built around you.Licensed US clinicians·Third-party tested
The Peptide Knowledge Base
Stack verdict, Not available

Only as available as its most restricted ingredient, here, injectable GHK-Cu, which is not available.

GLOW stack

GLOW adds a copper peptide (GHK-Cu) to the Wolverine base, a three-peptide blend pitched for skin, collagen, and tissue repair, usually sold as a single injectable.

Last reviewed June 16, 2026.

The honest answer

GLOW takes the Wolverine repair pair and adds GHK-Cu, a copper peptide, for a skin-and-appearance tilt, collagen, matrix, tone. Two things matter before anything else: it's sold as a single injectable, and topical cosmetic GHK-Cu is a completely different, legal product from the injectable form used here. As a blend it has never been tested in a clinical trial.

What the evidence shows
  • GHK-Cu is one of the better-studied copper peptides for collagen and matrix signaling, as a topical cosmetic.
  • BPC-157 and TB-500 carry the same animal-model repair evidence they do in Wolverine.
What the evidence does not show
  • The GLOW combination has never been studied as a product in any clinical trial.
  • It has even less combination evidence than Wolverine.
  • None of the three is FDA-approved for these uses.

Go deeper

The concept is three-axis coverage: BPC-157 for local tissue signaling, TB-500 for systemic cell migration, and GHK-Cu for matrix and collagen remodeling, a repair base with a skin-quality layer on top. That's the rationale people give for the blend. It's mechanistic reasoning, not a tested result, and it says nothing about how the blend should be used, which is a clinical question, not a recipe.

Anything on this page about GLOW refers to injectable blends, which we do not offer. Topical copper peptides for skin are a separate, legal category, see the Skin & Hair goal.

GLOW sits one rung up from Wolverine: it adds a peptide, and with it more variables and less combination evidence, not more proof.

StackWhat it addsCombination evidence
WolverineBPC-157 + TB-500The base repair pairAnimal-model data on each member; none on the combination
GLOW+ GHK-CuA copper peptide, tilting toward skin and appearanceEven less combination evidence than Wolverine
KLOW+ KPVAn anti-inflammatory, gut-leaning peptideThe least combination evidence of the three

Status & access

Not availableInjectable GHK-Cu, restricted (early-2027 review)

GLOW is an injectable blend, so we treat it as education only and do not offer it. Injectable GHK-Cu is restricted and under review for early 2027, it is not available. BPC-157 and TB-500 are on the July 23, 2026 PCAC agenda (advisory).

Compounded medications are prepared for an individual patient and are not FDA-approved. Removal from FDA Category 2 (April 2026) is not approval and not 503A Bulks-List eligibility. PCAC is advisory, a favorable vote leads to rulemaking, not instant availability.

Anything on this page about GLOW refers to injectable blends, which we do not offer. Topical copper peptides for skin are a separate, legal category, see the Skin & Hair goal.

Questions, answered first

What is the GLOW stack?

GLOW is a three-peptide injectable blend, the Wolverine pair (BPC-157 + TB-500) plus injectable GHK-Cu, a copper peptide, pitched for skin, collagen, and tissue repair. It's a community blend, not a clinical product, and it has never been studied as a combination.

Is injectable GHK-Cu legal?

No, injectable GHK-Cu is restricted and under FDA review projected for early 2027; it is not available. This is different from topical cosmetic GHK-Cu, which is an established, legal skincare ingredient. We never let the topical's legality imply the injectable's.

Is GLOW the same as topical copper peptide serums?

No. The copper peptide in a cosmetic serum (topical GHK-Cu) and the injectable GHK-Cu in a GLOW blend are different products with different rules. Topical is legal and available; the injectable blend is not. If you're after skin benefits, the topical/cosmetic route is the legal one, see the Skin & Hair goal.

Medically reviewed by the Peptós.LIFE clinical team · Last reviewed June 16, 2026. Educational content, not medical advice. We explain what the stack is and what the evidence shows; we don't publish doses, ratios, or how-to. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality.